| Literature DB >> 28849629 |
Toshiki Sawai1, Kaoru Dohi1, Naoki Fujimoto1, Setsuya Okubo2, Naoki Isaka3, Takehiko Ichikawa2, Katsutoshi Makino4, Shinya Okamoto5, Sukenari Koyabu6, Tetsuya Kitamura7, Toru Ogura8, Tomomi Yamada9, Satoshi Tamaru8, Masakatsu Nishikawa8, Mashio Nakamura1, Masaaki Ito1.
Abstract
This study investigated the effects and safety of eplerenone or thiazide diuretics in patients with hypertension and albuminuria (pretreatment urinary albumin/creatinine ratio ≥10 mg/gCr) treated with an angiotensin II receptor blocker. The primary end point was the mean percent change in the urinary albumin/creatinine ratio from baseline to 48 weeks. An efficacy analysis was performed in 195 patients (98 in the eplerenone group and 97 in the thiazide group). Systolic and diastolic blood pressures at 48 weeks were similar in the two groups. The mean percent change in the urinary albumin/creatinine ratio from baseline to 48 weeks was similar in the two groups (P=.804). In the safety analysis, the withdrawal rates for adverse events were similar in both groups. The antialbuminuric effects and safety of eplerenone therapy were similar to those of thiazide diuretics when combined with an angiotensin II receptor blocker in patients with hypertension and albuminuria. ©2017 Wiley Periodicals, Inc.Entities:
Keywords: antihypertensive therapy; clinical trials; combination therapy; proteinuria; renal disease
Mesh：
Substances：
Year: 2017 PMID： 28849629 PMCID： PMC8031246 DOI： 10.1111/jch.13054
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN： 1524-6175 Impact factor: 3.738